Currently, the only FDA-approved biomarkers for ICI therapy are PD-L1 expression of tumor tissue, tumor mutational burden, and DNA mismatch repair deficiency/microsatellite instability (for review, see [22]). This evidence concerns the gene CD274 and neoplasm.